These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Effects of potentiation and rapid action in models of venous thrombosis in dogs upon combined administration of the plasminogen tissue activator and urokinase modified by fibrinogen]. Maksimenko AV; Tishchenko EG; Petrova ML; Golubykh VL Biull Eksp Biol Med; 1996 Jan; 121(1):48-51. PubMed ID: 8680005 [No Abstract] [Full Text] [Related]
8. Evolving strategies for thrombolytic therapy of peripheral vascular occlusion. Valji K J Vasc Interv Radiol; 2000 Apr; 11(4):411-20. PubMed ID: 10787198 [No Abstract] [Full Text] [Related]
9. Thrombolytic effect of lonomin V in a rabbit jugular vein thrombosis model. Guerrero B; Arocha-Piñango CL; Pinto MA; Müller CA; Gil San Juan AG; Amorim S; Perales J Blood Coagul Fibrinolysis; 2001 Oct; 12(7):521-9. PubMed ID: 11685039 [TBL] [Abstract][Full Text] [Related]
10. Systemic thrombolysis for cerebral venous and dural sinus thrombosis: a systematic review. Viegas LD; Stolz E; Canhão P; Ferro JM Cerebrovasc Dis; 2014; 37(1):43-50. PubMed ID: 24356180 [TBL] [Abstract][Full Text] [Related]
11. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy. Collen D Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986 [No Abstract] [Full Text] [Related]
12. [New thrombolytic agents in myocardial infarction]. Charbonnier B; Lang M; Brochier M Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222 [TBL] [Abstract][Full Text] [Related]
13. New strategy of thrombolysis. Conjunctive effect of plasminogen activators with different pharmacokinetic profile. Maksimenko AV Ann N Y Acad Sci; 1998 Dec; 864():96-105. PubMed ID: 9928084 [TBL] [Abstract][Full Text] [Related]
14. Intravenous or intra-arterial thrombolysis?: it's time to find the right approach for the right patient. Mattle HP Stroke; 2007 Jul; 38(7):2038-40. PubMed ID: 17540964 [No Abstract] [Full Text] [Related]
15. Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir). Schneider J; Wnendt S; Saunders D; Heinzel-Wieland R; Wilffert B; Steffens G Eur J Pharmacol; 1996 Apr; 302(1-3):69-77. PubMed ID: 8790994 [TBL] [Abstract][Full Text] [Related]
16. [Thrombolytic agents, urokinase, tissue-type plasminogen activator and pro-urokinase--their routes of administration and dosage: comparison between intracoronary thrombolysis and intravenous coronary thrombolysis]. Motomiya T Nihon Rinsho; 2003 Apr; 61 Suppl 4():441-5. PubMed ID: 12735012 [No Abstract] [Full Text] [Related]
17. Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator. Gurewich V J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):16B-21B. PubMed ID: 3117859 [TBL] [Abstract][Full Text] [Related]